Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT) - Quiz - MDSpire

Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

  • By

  • Maohui Chen

  • Yizhou Huang

  • Shuliang Zhang

  • Cheng Chen

  • Taidui Zeng

  • Hongmu Li

  • Zhenyuan Yang

  • Chuanquan Lin

  • Wei Li

  • Benhua Xu

  • Chun Chen

  • Bin Zheng

  • March 9, 2026

  • 0 min

Share

Original Source(s)

Neoadjuvant Radiotherapy with Camrelizumab as a Chemotherapy-Sparing Strategy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase II Trial (ESOCORT-NIRT)

  • by Maohui Chen, Yizhou Huang, Shuliang Zhang, Cheng Chen, Taidui Zeng, Hongmu Li, Zhenyuan Yang, Chuanquan Lin, Wei Li, Benhua Xu, Chun Chen, Bin Zheng

  • March 9, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”